Want to join the conversation?
$FRED now expects 2016 total sales to increase 2-6% and comparable store sales to increase 1-4%. The change in outlook is primarily driven by the industry-wide slowdown in the Hepatitis C specialty drug market. EPS for 2016 are expected to $0.27-0.32 range. Adjusted EBITDA is forecasted to be $73-78MM, an increase of 35-45%.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.